Sex, drugs and trials galore
We are delighted to present you with the December 2015 issue of ISH Hypertension News.
This includes coverage of the results of four trials, all of which have important implications for clinical practice in relation to improving CVD prevention. Three of these trials - SPRINT and two PATHWAYS trials - have clinical implications for hypertension management (how low to go and how to do it) and one EMPA-REG provides unique data regarding optimal glucose lowering with a new class of agents for the prevention of CVD in patients with type 2 diabetes!
Latest Tweets: Follow us
The ISH is positively committed to opposing discrimination against people on the grounds of gender, race, colour, nationality, religion, marital status, sexual orientation, class, age, disability, having dependants, HIV status or perceived lifestyle.